Cancer Genetics looks for $48m in US IPO
This article was originally published in Clinica
Executive Summary
Personalised medicine firm Cancer Genetics is hoping to raise $48m in an initial public offering on the Nasdaq stock exchange in the US. The Rutherford, New Jersey company plans to sell four million shares priced at $11-13, with the $48m target is based on the company hitting a mid-price range of $12 per share; this would give it a market capitalisation of $111.9m.